Evaluating the Association of Initial Benzodiazepine Use and Antidepressant Adherence among Adults with Anxiety Disorders

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 6, 2012, Pages 338-344

  Wu, Chung Hsuen ^a   Farley, Joel F ^b   Gaynes, Bradley N ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antidepressant; Anxiety disorders; Benzodiazepine; Claims data

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG USE; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PANIC; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL PHOBIA; TREATMENT RESPONSE;

EID: 84871444930     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.10.007     Document Type: Article

References (43)

1. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
2. Greenberg P.E., Sisitsky T., Kessler R.C., Finkelstein S.N., Berndt E.R., Davidson J.R., Ballenger J.C., et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999, 60:427-435.
3. Olfson M., Fireman B., Weissman M.M., Leon A.C., Sheehan D.V., Kathol R.G., Hoven C., et al. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 1997, 154:1734-1740.
4. Stein M.B., Heimberg R.G. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J Affect Disord 2004, 79:161-166.
5. DuPont R.L., Rice D.P., Miller L.S., Shiraki S.S., Rowland C.R., Harwood H.J. Economic costs of anxiety disorders. Anxiety 1996, 2:167-172.
6. Fava M., Rush A.J., Alpert J.E., Balasubramani G.K., Wisniewski S.R., Carmin C.N., Biggs M.M., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008, 165:342-351.
7. Gaynes B.N., Magruder K.M., Burns B.J., Wagner H.R., Yarnall K.S., Broadhead W.E. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression?. Gen Hosp Psychiatry 1999, 21:158-167.
8. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder; 2004. Nov 2012. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1670530.
9. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. 2nd ed.; 2007. Nov 2012. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1678180.
10. American Psychiatric Association. Practice guideline for the treatment for patients with panic disorder. 2nd ed.; 2009. Nov 2012. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1680635.
11. Keene M.S., Eaddy M.T., Nelson W.W., Sarnes M.W. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care 2005, 11(12 Suppl):S362-S369.
12. Stein M.B., Cantrell C.R., Sokol M.C., Eaddy M.T., Shah M.B. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006, 57:673-680.
13. Bull S.A., Hunkeler E.M., Lee J.Y., Rowland C.R., Williamson T.E., Schwab J.R., Hurt S.W. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002, 36:578-584.
14. Masand P.S. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003, 25:2289-2304.
15. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder; 2010. Nov 2012. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485.
16. Rao S., Zisook S. Anxious depression: clinical features and treatment. Curr Psychiatry Rep 2009, 11:429-436.
17. Flint A.J. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging 2005, 22:101-114.
18. Lauderdale S.A., Sheikh J.I. Anxiety disorders in older adults. Clin Geriatr Med 2003, 19:721-741.
19. Karsnitz D.B., Ward S. Spectrum of anxiety disorders: diagnosis and pharmacologic treatment. J Midwifery Womens Health 2011, 56:266-281.
20. Nutt D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005, 10:49-56.
21. Goddard A.W., Brouette T., Almai A., Jetty P., Woods S.W., Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001, 58:681-686.
22. Pollack M.H., Simon N.M., Worthington J.J., Doyle A.L., Peters P., Toshkov F., Otto M.W. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003, 17:276-282.
23. Seedat S., Stein M.B. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004, 65:244-248.
24. Papakostas G.I., Clain A., Ameral V.E., Baer L., Brintz C., Smith W.T., Londborg P.D., et al. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 2010, 25:17-21.
25. McLaughlin T., Hogue S.L., Stang P.E. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther 2007, 14:221-225.
26. Peterson A.M., Nau D.P., Cramer J.A., Benner J., Gwadry-Sridhar F., Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.
27. Karve S., Cleves M.A., Helm M., Hudson T.J., West D.S., Martin B.C. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009, 25:2303-2310.
28. Liu X., Tepper P.G., Able S.L. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol 2011, 26:173-180.
29. Lader M. Benzodiazepines revisited-will we ever learn?. Addiction 2011, 106:2086-2109.
30. Flint A.J., Gagnon N. Diagnosis and management of panic disorder in older patients. Drugs Aging 2003, 20:881-891.
31. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
32. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
33. Inouye S.K., Zhang Y., Jones R.N., Shi P., Cupples L.A., Calderon H.N., Marcantonio E.R. Risk factors for hospitalization among community-dwelling primary care older patients: development and validation of a predictive model. Med Care 2008, 46:726-731.
34. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
35. Parsons L.S. Reducing bias in a propensity score matched-pair sample using greedy matching techniques 2001, Ovation Research Group, Seattle, WA.
36. SAS/STAT 9.2 user's guide 2008, SAS Institute Inc, SAS Institute Inc, Cary, NC.
37. Sirey J.A., Bruce M.L., Alexopoulos G.S., Perlick D.A., Friedman S.J., Meyers B.S. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv 2001, 52:1615-1620.
38. Interian A., Martinez I.E., Guarnaccia P.J., Vega W.A., Escobar J.I. A qualitative analysis of the perception of stigma among Latinos receiving antidepressants. Psychiatr Serv 2007, 58:1591-1594.
39. Sirey J.A., Bruce M.L., Alexopoulos G.S., Perlick D.A., Raue P., Friedman S.J., Meyers B.S. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 2001, 158:479-481.
40. Brown C., Battista D.R., Bruehlman R., Sereika S.S., Thase M.E., Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005, 43:1203-1207.
41. Russell J., Kazantzis N. Medication beliefs and adherence to antidepressants in primary care. N Z Med J 2008, 121:14-20.
42. Karve S., Cleves M.A., Helm M., Hudson T.J., West D.S., Martin B.C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008, 46:1125-1133.
43. Steiner J.F., Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997, 50:105-116.